Growing pain market to bode well for IX Biopharma

It has five drugs under development.

Combining with the sublingual delivery method to improve drug absorption and bioavailability to achieve a lower dosage, iX Biopharma’s products could potentially be key drugs in their respective market segments, said DBS Vickers Securities.

iX Biopharma, a speciality pharmaceutical company with expertise in formulation and drug delivery, currently has five drugs under development – three are for pain management: WafermineTM, BnoXTM and WafernylTM; WafeRestTM for jetlag and improved sleep quality; and PheoniXTM for the treatment of male erectile dysfunction.

According to DBS Vickers Securities, the global pain management is growing, especially with the ageing population.

"We expect iX Biopharma to capture a significant market share once WafermineTM and BnoXTM are ready for commercialisation and exportation, likely in late 2018/ early 2019," it said.

The research firm added that to fund further R&D and clinical operations and to accelerate profitability, iX Biopharma could explore out-licensing opportunities likely in 3Q17.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia